-
Pfizer has recalled multiple injection drugs containing glass particles, but none of them have entered the Chinese market
Pfizer has recalled several injection drugs with glass particles, but none of them have entered the Chinese market. The official website of the US Food and Drug Administration (FDA) recently issued t ... -
Lilly Plus Kanezumab Injection Approved in China for Preventive Treatment of Adult Migraine
On January 10th, Lilly Pharmaceuticals announced that Encore&Co; Reg; Jiakanezumab Injection has officially been approved by the National Medical Products Administration for the preventive treatment ... -
Lilly Pharmaceuticals and Kanezumab Injection Approved for Preventive Treatment of Adult Migraine in China
On January 10th, Lilly Pharmaceuticals announced that Encore&Co; Reg; Jiakanezumab Injection has officially been approved by the National Medical Products Administration for the preventive treatment ... -
Novo Nordisk: Positive progress made in reducing the risk of kidney disease with Smegglutide injections
On March 5th, Danish time, Novo Nordisk announced that its widely used semaglutide injection has made positive progress in treating kidney disease in a double-blind trial called FLOW. Compared with t ... -
Novo Nordisk Smegglutide Injection Approved for Weight Loss Indications in China
On June 25th, Novo Nordisk announced that its new indication for Smegglutide Injection has been approved by the National Medical Products Administration for listing (trade name: Novo Nordisk) as an a ... -
Novo Nordisk Smegglutide Injection Approved for Weight Loss Indications in China
On June 25th, Red Star Capital Bureau reported that the National Medical Products Administration recently approved the listing application of Novo Nordisk's research and production of Novo Nordisk's ... -
Novartis antibody new drug Busizumab injection new indication declared for market in China
On October 12th, the official website of the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) announced that Novartis' application for the listing of Busizumab ...